CTMX Varseta-M reports robust late-line CRC efficacy
TradingView reports a conference highlighted strong clinical progress for Varseta-M in late-line colorectal cancer, with promising efficacy and safety, plus a pivotal study planned for next year.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.